Lab-Developed Tests: FDA Gives Extra Time For Input On Oversight Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
Comments submitted thus far largely do not offer detailed suggestions for alternative regulatory regimes, but highlight particular areas in which the agency should take caution.
You may also be interested in...
FDA Gathers Feedback To Guide Oversight Of Lab-Developed Testing
FDA says it will tailor its future oversight of laboratory tests and services based on risk, but experts warn that "high risk" will be hard to define for these diagnostics
FDA Aims To Finalize Framework For Lab-Developed Tests In Near Term
FDA could have a final framework in place for overseeing a greatly expanded range of laboratory test services within months of a public meeting scheduled for July, according to agency officials
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.